Table 2.
HFpEF-specific characteristics.
| Clinical Characteristics | HFpEF |
|---|---|
| Echocardiography | |
| Ejection fraction (%) | 61 ± 2 |
| LV IVSd (cm) | 1.17 ± 0.04 |
| LV PWd (cm) | 1.22 ± 0.11 |
| LV ID diastole (cm) | 4.52 ± 0.12 |
| LD ID systole (cm) | 4.58 ± 0.07 |
| Peak E wave (cm/s) | 98 ± 5 |
| Peak A wave (cm/s) | 92 ± 7 |
| E/A ratio | 1.36 ± 0.17 |
| E’ lateral wall (cm/s) | 8 ± 1 |
| E/E’ ratio | 22 ± 8 |
| Disease-specific Biomarkers | |
| BNP (pg/ml) | 150 ± 26 |
| NT-pro BNP (pg/ml) | 620 ± 165 |
| ST2 (ng/ml) | 45 ± 6 |
| Galectin-3 (ng/ml) | 15 ± 1 |
| Cystatin C (ng/ml) | 17 ± 1 |
| Comorbidities | |
| COPD (%) | 7 |
| Diabetes (%) | 33 |
| CAD (%) | 29 |
| Hypertension (%) | 71 |
| Medications | |
| Beta receptor blocker (%) | 45 |
| ACEi or ARB (%) | 60 |
| Loop diuretics (%) | 81 |
| Diuretic (%) | 69 |
| Statin (%) | 67 |
| Calcium channel blockers (%) | 19 |
LV IVSD, left ventricle interventricular septum; LV PWd, left ventricle posterior wall diameter; LV ID, left ventricle internal diameter; COPD, chronic obstructive pulmonary disease; CAD, coronary artery disease; angiotensin converting enzyme inhibitor; angiotensin receptor blocker; BNP, B-type natriuretic peptide; NT-proBNP, NT-pro B-type natriuretic peptide; ST2, suppression of tumorigenicity 2. Data are mean ± SEM or %.